Cystic fibrosis is the most common fatal genetic disease in western countries. It affects one out of every 2,500 births and patients have a 35-year life expectancy. There is currently no cure for cystic fibrosis. The Air Liquide Foundation supports research carried out by the Université Libre de Bruxelles in order to fight this disease.
A new hope for treatment
A novel class of antibodies known as nanobodies has been discovered, offering hope for treating cystic fibrosis. These nanobodies are smaller than traditional antibodies. The project examining this new approach is led by the Université Libre de Bruxelles with support from the Air Liquide Foundation.
The Air Liquide Foundation team
Fondation Air Liquide
75 Quai d'Orsay